Improving the anti-diabetic activity of GLP-1 by fusion with globular adiponectin

Artificial Cells, Nanomedicine and Biotechnology

Volumn 41, Issue 3, 2013, Pages 159-164

  Gao, Mingming ^a   Tong, Yue ^a   Li, Wen ^a   Gao, Xiangdong ^a   Yao, Wenbing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Adiponectin; Diabetes; Glucagon like peptide 1; Incretin; Protein engineering

Indexed keywords

ADIPONECTIN; ANTI-DIABETIC DRUGS; GLUCAGON-LIKE PEPTIDE-1; GLUCOSE TOLERANCE TEST; INCRETIN; ORAL GLUCOSE TOLERANCE TESTS; PROTEIN ENGINEERING; RECOMBINANT EXPRESSION;

GENETIC ENGINEERING; GLUCOSE; MEDICAL PROBLEMS; PEPTIDES; TISSUE;

MAMMALS;

ADIPONECTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 GLOBULAR ADIPONECTIN FUSION PROTEIN; GLUCOSE; HYBRID PROTEIN; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS FUNCTION; PANCREAS INJURY; PROTEIN EXPRESSION; PROTEIN PURIFICATION; STREPTOZOCIN DIABETES;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; ESCHERICHIA COLI; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; INJECTIONS, INTRAPERITONEAL; INSULIN; MALE; MICE; PANCREAS; PROTEIN FOLDING; RECOMBINANT FUSION PROTEINS; STREPTOZOCIN;

MUS;

EID: 84878481281     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/10731199.2012.712042     Document Type: Article

References (23)

1. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O. 1994. Structureactivity studies of glucagon-like peptide-1. J Biol Chem. 269 : 6275-6278.
2. Baggio LL, Drucker DJ. 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology. 132: 2131-2157.
3. Baggio LL, Huang Q, Brown TJ, Drucker DJ. 2004. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 53: 2492-2500.
4. Burcelin R, Dolci W, Th orens B. 1999. Long-lasting antidiabetic eff ect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism. 48: 252-258.
5. Drucker DJ, Nauck MA. 2006. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368: 1696-1705.
6. Gao M, Ma C, Liu WC, Zhu J, Tian H, Gao XD, Yao W. 2010. Production and purifi cation of an analog of glucagon-like peptide-1 by auto-induction and on-column cleavage in Escherichia coli. World J Microbiol Biotechnol. 26: 1675-1682.
7. Gao M, Tian H, Ma C, Gao X, Guo W, Yao W. 2010. Expression, purifi cation, and C-terminal site-specifi c PEGylation of cysteinemutated glucagon-like peptide-1. Appl Biochem Biotechnol. 162 : 155-165.
8. Holst JJ. 2007. The physiology of glucagon-like peptide 1. Physiol Rev. 87: 1409-1439.
9. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 116: 1784-1792.
10. Kim BJ, Zhou J, Martin B, Carlson OD, Maudsley S, Greig NH, Mattson MP, et al. 2010. Transferrin fusion technology: A novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Th er. 334: 682-692.
11. Ma C, Gao M, Liu W, Zhu J, Tian H, Gao X, Yao W. 2010. Intein-mediated expression and purifi cation of an analog of glucagon-like peptide-1 in Escherichia coli. Protein Pept Lett. 17 : 1245-1250.
12. McEvoy RC, Andersson J, Sandler S, Hellerstrom C. 1984. Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. J Clin Invest. 74: 715-722.
13. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. 2010. Glycaemic variability and complications in patients with diabetes mellitus: Evidence from a systematic review of the literature. Diabetes Obes Metab. 12: 288-298.
14. Nielsen LL. 2005. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today. 10: 703-710.
15. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, et al. 2003. Structure-function studies of the adipocytesecreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem. 278: 9073-9085.
16. Rolin B, Larsen MO, Gotfreds en CF, Deacon CF, Carr RD, Wilken M, Knudsen LB. 2002. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 283: E745-E752.
17. Siegel EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Folsch UR, Schrezenmeir J, et al. 1999. Biological activity of GLP-1-analogues with N-terminal modifi cations. Regul Pept. 79: 93-102.
18. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ III. 2011. The eff ects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, doubleblind study of overweight/obese patients with type 2 diabetes: The EGO study. Diabetes Obes Metab. 13: 418-425.
19. Veronese FM, Pasut G. 2005. PEGylation, successful approach to drug delivery. Drug Discov Today. 10: 1451-1458.
20. Xu G, Stoff ers DA, Habener JF, Bonner-Weir S. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 48: 2270-2276.
21. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, et al. 2010. Prevalence of diabetes among men and women in China. N Engl J Med. 362 : 1090-1101.
22. Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC. 2007. Evaluation of therapeutic potentials of site-specifi c PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol. 73: 84-93.
23. Zhao HL, Yao XQ, Xue C, Wang Y, Xiong XH, Liu ZM. 2008. Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering. Protein Expr Purif. 61: 73-77.